How Does Edwards Lifesciences Make its Money?
Edwards Lifesciences is the global leader in transcatheter heart valves and hemodynamic monitoring. The company pioneered the field of transcatheter aortic valve replacement (TAVR) with its SAPIEN platform, which allows doctors to replace diseased heart valves without open-heart surgery. Edwards commands over 60% of the global TAVR market and has been expanding into transcatheter mitral and tricuspid valve repair and replacement — a massive untapped opportunity. The company recently sold its Critical Care business to focus entirely on structural heart therapies.
Edwards Lifesciences (EW) Business Model
Edwards Lifesciences operates in the medical devices sector. Below is a summary of Edwards Lifesciences’ revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Edwards Lifesciences’ 2024 fiscal year filings with the SEC.
Edwards Lifesciences Competitors
Edwards Lifesciences’s key competitors and comparable public companies in the medical devices sector include Medtronic, Boston Scientific, Abbott Laboratories, and Intuitive Surgical. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Edwards Lifesciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Edwards Lifesciences Competitors
Edwards Lifesciences’s key competitors and comparable public companies in the medical devices sector include Medtronic, Boston Scientific, Abbott Laboratories, and Intuitive Surgical. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Edwards Lifesciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Edwards Lifesciences Competitors
Edwards Lifesciences’s key competitors and comparable public companies in the medical devices sector include Medtronic, Boston Scientific, Abbott Laboratories, and Intuitive Surgical. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Edwards Lifesciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Edwards Lifesciences Competitors
Edwards Lifesciences’s key competitors and comparable public companies in the medical devices sector include Medtronic, Boston Scientific, Abbott Laboratories, and Intuitive Surgical. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Edwards Lifesciences stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Segment | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Transcatheter Aortic Valve Replacement (TAVR) | $4,200 | $3,900 | +7.7% |
| Transcatheter Mitral & Tricuspid Therapies (TMTT) | $300 | $200 | +50.0% |
| Surgical Structural Heart | $1,100 | $1,000 | +10.0% |
| Total Revenue | $5,600 | $5,800 | -3.4% |
Transcatheter Aortic Valve Replacement (TAVR) — 75% of Revenue
Transcatheter Mitral & Tricuspid Therapies (TMTT) — 5% of Revenue
Surgical Structural Heart — 20% of Revenue
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $5,600 | $5,800 |
| Cost of Revenue | $1,300 | $1,400 |
| Gross Profit | $4,300 | $4,400 |
| Operating Expenses | $2,400 | $2,500 |
| Operating Income | $1,900 | $1,900 |
| Net Income | $1,400 | $1,500 |
All values in millions USD unless otherwise stated.
Key Financial Metrics
- Gross Margin: 76.8%
- Operating Margin: 33.9%
- Revenue Growth: -3.4%
Is Edwards Lifesciences Profitable?
Yes, Edwards Lifesciences is profitable. The company reported net income of $1,400 on total revenue of $5,600. With an operating margin of 33.9%, Edwards Lifesciences demonstrates solid profitability for the medical devices sector. The gross margin of 76.8% reflects Edwards Lifesciences’ pricing power and cost structure.
What to Watch
- TAVR volume growth as therapy expands to treat moderate aortic stenosis
- TMTT pipeline progress — transcatheter mitral and tricuspid repair/replacement
- Post-Critical Care divestiture: focus and margin profile as a pure structural heart company
- International TAVR adoption, particularly in underpenetrated Asian markets
Edwards Lifesciences (EW) Financial Summary
Edwards Lifesciences (EW) is a medical devices company that generated $5,600 in total revenue in fiscal year 2024. Revenue grew -3.4% year-over-year. The company earned $1,400 in net income, making it profitable. For a deeper look at Edwards Lifesciences’ revenue breakdown, business segments, and financial performance, review the detailed analysis above.